Incorporation of ICI into HR+/HER2− or HER2+ breast cancer has been hindered by its poor immunogenicity, and many novel combination strategies aim to convert immune cold tumors into immune hot tumors and increase the immunogenicity of HR+/HER2− breast cancer. Here, ERBB2 is linked to breast cancer.